Results

Total Results: 2,078 records

Showing results for "drugs".

261. Treatment of Dementia Among Community-Dwelling and Institutionalized Medicare Beneficiaries | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/dementia-databases-methods/research
     May 22, 2008 - Use of anti-dementia drugs was similar across settings, with 24.7% of dementia cases in the community … larger than in the community, but there is little difference in the proportions receiving anti-dementia drugs … 12 In a previous study, the authors 13 reviewed 81 recent randomized clinical trials of dementia drugs … Our analysis of drugs typically used to treat behavioral manifestations of dementia found that treatment … these utilization rates are not adjusted for potential confounding factors, we cannot conclude the drugs

262. #06 Developmental Delays ADHD, and Autism (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/developmental-delays-horizon-scan-high-impact-1312.pdf
     December 01, 2013 - Coordinating Council for Comparative Effectiveness Research, AHRQ is interested in innovations in drugs … health care sector, horizon scanning pertains to identification of new (and new uses of existing) pharmaceuticals … For purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs, devices, procedures … Information is compiled for expert comment on topics at a granular level (i.e., similar drugs in the … Autism treatments and drugs. [internet].

263. Diabetes Mellitus (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/07_diabetes_potential_high_impact_2012-12-10.pdf
     January 01, 2012 - In the health care sector, horizon scanning pertains to identifying new (and new uses of existing) pharmaceuticals … These therapies are extended-release exenatide for injection (Bydureon ™ , Amylin Pharmaceuticals, … Extended-release exenatide (exenatide once-weekly [EQW]; Bydureon™, Eli Lilly and Co., Indianapolis, IN, Amylin Pharmaceuticals … San Diego (CA): Amylin Pharmaceuticals, Inc.; 2012 Jan 27 [accessed 2012 Feb 20]. [4 p]. … San Diego (CA): Amylin Pharmaceuticals, Inc.; 2012 Jan 27. 11 p.

264. Diabetes Mellitus (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/07_diabetes_potential_high_impact_2012-12-10.pdf
     January 01, 2012 - In the health care sector, horizon scanning pertains to identifying new (and new uses of existing) pharmaceuticals … These therapies are extended-release exenatide for injection (Bydureon ™ , Amylin Pharmaceuticals, … Extended-release exenatide (exenatide once-weekly [EQW]; Bydureon™, Eli Lilly and Co., Indianapolis, IN, Amylin Pharmaceuticals … San Diego (CA): Amylin Pharmaceuticals, Inc.; 2012 Jan 27 [accessed 2012 Feb 20]. [4 p]. … San Diego (CA): Amylin Pharmaceuticals, Inc.; 2012 Jan 27. 11 p.

265. Disposition of Comments Report for Treatment of Atrial Fibrillation (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/atrial-fibrillation_disposition-comments.pdf
     June 28, 2013 - And for KQ4, comparing anti-arrhythmic drugs (AADs) with electrical cardioversion for restoration of … We have added additional information about whether the drugs were given IV, orally, or a combination … Mascette ES (Results) The inclusion of amiodarone and sotalol as rate-control drugs (pp. … Mascette Results A gender difference in efficacy of drugs (but not proarrhythmia) is mentioned on … Comparative efficacy of rate control drugs is a good example.

266. Arthritis and Nontraumatic Joint Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/arthritis-horizon-scan-high-impact-1512.pdf
     December 29, 2015 - health care sector, horizon scanning pertains to identification of new (and new uses of existing) pharmaceuticals … Results The table below lists four topics for which (1) preliminary phase III data for drugs were … Treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs) are used for first-line therapy to … Novartis Pharmaceuticals. 16 week efficacy and 2 year long term safety and efficacy of secukinumab … Novartis Pharmaceuticals. 16 week efficacy and 5 year long term efficacy, safety and tolerability

267. PEPTIC ULCER #11 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/peptic-ulcer-horizon-scan-high-impact-1512.pdf
     December 01, 2015 - Results The table below lists two topics for which (1) preliminary phase III data for drugs or phase … We continue tracking novel drugs and interventions such as fecal microbiota therapy for ulcerative … Raleigh (NC): Salix Pharmaceuticals, Inc.; 2014 Mar. 19 p. 34. Salix Pharmaceuticals, Inc. … Raliegh (NC): Salix Pharmaceuticals, Inc.; 2015 May. 7 p. … Raleigh (NC): Salix Pharmaceuticals; 1 p.

268. Management of Primary Headache During Pregnancy | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/headaches-pregnancy/protocol
     November 12, 2019 - For example, nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to be associated with a higher … Antiepileptic drugs (e.g., divalproex sodium, sodium valproate, valproic acid, topiramate, gabapentin … Nonsteroidal antiinflammatory drugs (NSAIDs) (e.g., ibuprofen, naproxen, aspirin, celecoxib, ketorolac … Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. … https://www.fda.gov/drugs/drugsafety/ucm350684.htm . Accessed on March 23, 2019.  16. Andrade C.

269. Female | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/health-topics/female
     September 20, 2021 - Telehealth for Women Research Protocol September 20, 2021 Long-Term Drug Therapy and Drug Holidays for Osteoporotic Fracture Prevention Research Protocol April 12, 2018 Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review …

270. #05 DEPRESSION (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/05_depression_potential_high_impact_june_2012.pdf
     January 01, 2012 - In the health care sector, horizon scanning pertains to identifying new (and new uses of existing) pharmaceuticals … several weeks, following a single infusion. 37,41,42 The drug was originally launched by King Pharmaceuticals … Drugs Future 2009;34(3):217-21. 39. Thomson Reuters Integrity [database online]. … In: Drugs@FDA [internet]. Silver Spring (MD): U.S. … Available: http://www.accessdata.fda.gov/scripts/cder/drugs atfda/index.cfm?

271. S158 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s158.pdf
     October 01, 2007 - Measures: Association between nonsteroidal antiinflammatory drugs (NSAIDs) and mortality. … In addition, frail elderly patients, who use the most drugs and have the highest adverse event rates, … These databases are, however, often the best source of information on the association between drugs and … diseases, because they allow timely assessment of infrequently used drugs and rare outcomes in large … Selective prescribing led to overestimation of the benefits of lipid-lowering drugs.

272. Disposition of Comments: CER 228, Nonopioid Pharmacologic Treatments for Chronic Pain (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-228-nonopioid-pharm-chronic-pain-comments.pdf
     April 16, 2020 - of 4 will addict, then there would be ~25 million Americans addicted, and actively seeking illicit drugs … This was a 13-week randomized trial comparing escitalopram with duloxetine and showed that both drugs … Each of the pharmaceuticals studied have unique profiles that make them clinically appropriate for … ASRA recognizes that all drugs – opioid and nonopioid – carry risks. … This report examines the evidence-base for nonopioid drugs used to treat chronic pain, varying by pain

273. Pharmacological treatment | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/health-topics/pharmacological-treatment
     February 12, 2019 - Treatment of Acute Pain: An Evidence Map Research Protocol February 12, 2019 Managing Gout Consumer Summary Archived January 31, 2017 Management of Gout Research Protocol Archived November 3, 2014 Long-Term Drug Therapy and Drug Holidays for Osteopor…

274. What do we know about how evidence of harm and benefit is communicated in other countries? (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/communicating_risk_international_king.ppt
     January 01, 2005 - Methods Literature Review Medline--1996-2006 Search Terms: Patient Education Evidence-based Medicine Pharmaceutical … Preparations Consumer Information Products from Other Countries Description Compare characteristics

275. Infectious Disease Including HIV/AIDS #09 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/09_infectiousdisease_potential_high_impact_june_2012.pdf
     January 01, 2012 - Optimer Pharmaceuticals announced a 2-year agreement with Cubist Pharmaceuticals, Inc. … Tibotec Pharmaceuticals, Vertex Pharmaceuticals. … Cambridge (MA): Vertex Pharmaceuticals, Inc.; 2012 Feb 23 [accessed 2012 May 21]. [5 p]. … Cambridge (MA): Vertex Pharmaceuticals Incorporated; [accessed 2012 May 17]. [3 p]. … San Diego (CA): Optimer Pharmaceuticals, Inc.; 2011 [accessed 2011 Jul 21]. [4 p].

276. Disposition of Comments for CER 208 Treatment for Bipolar Disorder in Adults A Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-208-bipolar-adults-disposition-comments.pdf
     August 07, 2018 - Introduction Peer Reviewer #6 “Drugs for acute mania are generally used for shorter periods than … drugs used for treating depression or for maintenance.” – This is often not the case. … The statement is not true of other drugs. Thank you for the clarification. … We revised the sentence to read that some drugs may increase these risks. … Perhaps for clarity “Other drugs for acute mania” could be relabeled “Drugs Not Approved by FDA For

277. Horizon-Scan Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/horizon-scan_research-protocol.pdf
     December 01, 2011 - Coordinating Council for Comparative Effectiveness Research, AHRQ is interested in innovations in drugs … health care sector, horizon scanning pertains to identification of new (and new uses of existing) pharmaceuticals … If so, do not select, because these are “me-too” of existing drugs. … Covers future industry trends, key industry developments, research and development of drugs and pharmaceuticals … Industries covered: pharmaceuticals, biotechnology, medical equipment & devices, and in vitro diagnostics

278. Arthritis-Psoriatric Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/arthritis-psoriatric_executive.pdf
     April 01, 2012 - Available therapies for PsA include corticosteroids, oral disease-modifying antirheumatic drugs or … Effective Health Care infliximab) are also classified as antitumor necrosis factor (anti-TNF) drugs … Finally, very little is known about the benefits or risks of these drugs in different patient subgroups … Analytic framework for treatment for psoriatic arthritis DMARDS = disease-modifying antirheumatic drugs … Discussion No head-to-head controlled trials meeting inclusion criteria existed for any drugs in this

279. Point-Of-Care Research (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/point-of-care_research.pdf
     April 01, 2014 - We typically did not review evidence summaries on specific interventions, such as specific drugs or … Dietary Supplements in Adults Taking Cardiovascular Drugs. … Interactions of commonly used dietary supplements with cardiovascular drugs: a systematic review. … Dietary Supplements in Adults Taking Cardiovascular Drugs. … Interactions of commonly used dietary supplements with cardiovascular drugs: a systematic review.

280. Summary Variables in Observational Research: Propensity Scores and Disease Risk Scores | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/observational-research-scores/research
     May 15, 2012 - In this example, we assume that there are nine individual drugs of interest, six traditional NSAIDs and … Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. … COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. … COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. … Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.